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The emergence of resistance to cisplatin is a serious drawback of cancer therapy. 
To help elucidate the molecular basis of this resistance, we examined matched ovarian 
cancer cell lines that differ in their DNA mismatch repair (MMR) status and the response 
to cisplatin. Checkpoint activation by cisplatin was identical in both lines. However, sensi‑
tive cells delayed S‑phase transition, arrested at G2/M and died by apoptosis. The G2/M 
block was characterized by selective disappearance of homologous recombination (HR) 
proteins, which likely resulted in incomplete repair of the cisplatin adducts. In contrast, 
resistant cells transiently arrested at G2/M, maintained constant levels of HR proteins and 
ultimately resumed cell cycle progression. The net contribution of MMR to the cisplatin 
response was examined using matched semi‑isogenic (HCT116±chr3) or strictly isogenic 
(293T‑La‑/+) cell lines. Delayed transition through S‑phase in response to cisplatin was 
also observed in the MMR‑proficient HCT116+chr3 cells. Unlike in the ovarian cell lines, 
however, both HCT116+chr3 and HCT116 permanently arrested at G2/M with an intact 
complement of HR proteins and died by apoptosis. A similar G2/M arrest was observed 
in the strictly isogenic 293T‑La‑/+ cells. This confirmed that although MMR undoubtedly 
contributes towards the cytotoxicity of cisplatin, it is only one of several pathways that 
modulate the cellular response to this drug. However, our data highlighted the impor‑
tance of HR to cisplatin cytotoxicity and suggested that HR status might represent a novel 
prognostic marker and possibly also a therapeutic target, the inhibition of which would 




























metabolic	 changes	 were	 suggested	 to	 contribute	 to	 the	 acquisition	 of	 drug	 resistance.	
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Among	 those,	 an	 increase	 in	 glutathione	 (GSH)	 concentration,	
proportional	to	the	degree	of	cisplatin	resistance,	suggested	a	role	for	
GST	in	the	detoxification	processes.26	Moreover,	facilitated	excretion	
of	 cisplatin	 and	 enhanced	 repair	 of	 DNA	 adducts	 were	 proposed	
to	be	 other	 possible	mechanisms	of	 resistance.2	 Study	of	 the	 stress	
signals	triggered	by	cisplatin-induced	DNA	damage	have	implicated	












found	 that	 the	 ability	 to	maintain	 functional	 homologous	 recom-




line	 was	 derived	 from	 the	 hMLH1-deficient	 HEK293T	 cells	 by	
stable	transfection	with	a	vector	carrying	the	hMLH1	cDNA	under	
the	 control	 of	 the	 inducible	Tet-Off	 expression	 system.33	The	 cells	
were	 grown	 in	 DMEM	 with	 Eagle	 salts	 (Life	 Technologies,	 Inc.,	
Rockville,	 MD),	 supplemented	 with	 10%	 Tet-System	 approved	
fetal	 bovine	 serum	 (Clontech,	Palo	Alto,	CA),	 2	mM	L-glutamine	
(Life	 Technologies),	 100	 IU/ml	 penicillin,	 100	 mg/ml	 strepto-
mycin	 (Life	 Technologies),	 100	 mg/ml	 Zeocin	 (Invitrogen,	 San	




The	 human	 colon	 cancer	 cell	 line	HCT116	 and	 its	 hMLH1-pro-
ficient	 subline	 HCT116+chr334	 were	 maintained	 in	 McCoy’s	 5A	
medium	(Life	Technologies)	with	10%	fetal	calf	serum	(FCS)	(Life	
Technologies),	 penicillin	 and	 streptomycin.	 In	 order	 to	 maintain	
the	 expression	 of	 chromosome	 3,	 400	mg/mL	G418	was	 added	 to	
the	medium.	The	human	ovarian	carcinoma	cell	 line	A2780	and	a	






Chemicals and antibodies.	 Cisplatin	 was	 obtained	 from	
Sigma	(St.	Louis,	MO)	and	dissolved	in	DMSO,	as	specified	by	the	
manufacturer.
Anti-hMLH1	 (554072),	 anti-hPMS2	 (556415)	 and	
anti-hRad51	 (551922)	 were	 from	 BD	 Pharmingen	 (S.	 Jose,	 CA);	
anti-hChk1-pSer345,	anti-hChk2-pThr68	and	anti-p95-Nbs1-pSer343	
were	 obtained	 from	 Cell	 Signaling	 Technology	 (Beverly,	 MA);	
anti-hChk1	 (611152)	 and	 anti-hMSH6	 (clone	 44,	 G70220)	 were	
purchased	 from	 BD	 Transduction	 Laboratories	 (S.	 Jose,	 CA);	
anti-hTFIIH	p89	(sc-19),	anti-p53	(Pab	1801),	anti-FANCD2	(FI17,	
sc-20022),	anti-BRCA1	(D-9,	 sc-6954),	anti-PCNA	(PC10,	 sc-56)	
and	 anti-b-tubulin	 (D-10)	 were	 from	 Santa	 Cruz	 Biotechnology	
(S.	Cruz,	CA);	anti-p95-Nbs1	(Ab398)	was	obtained	from	Abcam;	
anti-BRCA2	 (Ab-1)	was	 from	Calbiochem	 (Darmstadt,	Germany);	
anti-hChk2	(07-126),	anti-hCdk1	(06-966),	anti-gH2AX-pSer139	and	
anti-histone	H3-pSer10	 (06-570)	were	 from	Upstate	Biotechnology	
(Charlottesville,	 VA);	 anti-RPA-p34	 (Ab-3),	 anti-p21WAF1	 (Ab-1,	
OP64)	 and	 anti-hMRE11	 (Ab-1,	 PC388)	 were	 from	 Oncogene	
(S.	 Jose,	 CA);	 anti-ATM	 pSer1981	 was	 obtained	 from	 Rockland	
(Gilbertsville,	PA)	and	anti-ATM	was	kindly	provided	by	Stephen	P.	
Jackson	(Wellcome/CRC	Institute,	Cambridge,	UK).
Western blot analysis.	 Cellular	 proteins	 were	 extracted	 using	
ice-cold	 buffer	 A	 (50	 mM	 Tris-HCl	 pH	 7.5,	 120	 mM	 NaCl,	
20	mM	NaF,	1	mM	EDTA,	6	mM	EGTA,	15	mM	Na-pyrophosphate,	
0.5	mM	Na-orthovanadate,	 1	mM	benzamidine,	 0.1	mM	phenyl-
methylsulfonil	 fluoride	 (PMSF),	 1%	 Nonidet	 P-40).	 Protein	
concentration	 was	 determined	 using	 the	 Bio-Rad	 Protein	 Assay	
Reagent	(Bio-Rad,	Hercules,	CA).	Detection	of	proteins	by	Western	
blot	analysis	was	performed	following	separation	of	50	mg	whole	cell	
extracts	 on	 SDS-polyacrylamide	 gels.	 Proteins	 were	 transferred	 to	
a	Polyvinylidene	Fluoride	 (PVDF)	membrane,	 probed	with	 appro-
priate	 antibodies	 and	 immune	 complexes	 revealed	 using	 the	 ECL	
system	(Amersham-Pharmacia,	Uppsala,	Sweden).
Immunofluorescence.	Indirect	immunofluorescence	experiments	
were	 performed	with	 cells	 grown	 on	 acid-washed	 glass	 cover-slips.	
Fixation	was	done	in	ice-cold	methanol	(20	min	at	-20˚C).	Proteins	
were	 visualized	 by	 overnight	 incubation	 at	 4˚C	 using	 anti-gH2AX	
(1:100),	 anti-PCNA	 (1:200)	 and	 anti-H3-pS10	 (1:100).	 After	
washing,	the	cells	were	incubated	with	FITC-conjugated	anti-rabbit	
(1:750,	 Sigma)	 and	TR-conjugated	 anti-mouse	 antibodies	 (1:200,	






addition	 of	 the	 MTT	 solution	 (0.5	 mg/ml)	 (Sigma),	 plates	 were	
incubated	 for	 4-5	 h	 at	 37˚C.	One	 volume	 of	 lysis	 solution	 (20%	
SDS,	50%	dimethylformamide	pH	<4.7)	was	added	and	the	plates	
were	 incubated	 overnight	 at	 37˚C.	 The	 solubilized	 formazan	 was	
quantified	at	570	nm	using	a	Versamax	microplate	reader	(Molecular	
Devices,	Sunnyvale.	CA).	Optical	density	values	were	plotted	against	
the	 logarithm	 of	 cisplatin	 concentrations	 and	 IC50	 values	 were	
calculated	from	the	regression	curve.




with	propidium	iodide	(20	mg/ml,	Sigma)	and	 incubated	on	 ice	 in	
the	 dark	 for	 30	min.	DNA	 content	 was	 analyzed	 using	 a	Coulter	
FC500	Flow	Cytometer	(Beckman	Coulter	Inc.,	Fullerton,	CA)	and	
quantification	was	performed	with	the	software	WinMDI	2.8.
Quantification of S‑phase transition.	 Cells	 were	 seeded	 in	











The response of MMR‑proficient and 
‑deficient cell lines to cisplatin.	 A2780	 is	 a	
human	 ovarian	 cancer	 cell	 line,	 from	which	 a	
cisplatin	 resistant	 sub-line	 (CP70)	was	derived	
through	exposure	to	increasing	drug	concentra-
tions.35	 These	 matched	 cell	 lines	 are	 among	
the	 few	 examples	 of	 cells	 of	 ovarian	 origin	
displaying	 an	 altered	 MMR	 status.36	 A2780	
cells	 are	MMR-proficient,	 whereas	 CP70	 cells	
are	 MMR-deficient	 as	 a	 result	 of hMLH1	
gene	 promoter	 hypermethylation	 and	 conse-
quent	 lack	 of	MLH1	 expression.24	 In	 our	 cell	
viability	 assays,	 the	 CP70	 cells	 were	 ~10-fold	
more	resistant	to	killing	by	cisplatin	(Fig.	1A),	
as	 reported	 by	 others.37	 Clonogenic	 assays	
showed	that	matched	pairs	of	MMR-proficient	
and	 -deficient	 cells,	 such	 as	 the	 semi-isogenic	
HCT116±chr3	 cells,	 displayed	 only	 ~1.5-fold	
sensitivity	 differences	 to	 cisplatin.38	 Likewise,	
in	the	strictly	isogenic	HEK	293T-MutLa-/La+	
cells,	 which	 differ	 solely	 in	 the	 expression	 of	
hMLH1,33,39,40	 the	 sensitivity	 difference	 to	
cisplatin	was	~2-fold	(293T-MutLa-	IC50	=	5.3	
±	0.25	mM;	293T-MutLa+	IC50	=	2.65	±	0.35	
mM;	 and	 19).	These	 results	 indicated	 that	 the	
larger	difference	in	cisplatin	sensitivity	observed	
in	the	A2780/CP70	system	as	compared	to	the	
isogenic	cell	 lines	 is	 likely	attributable	 to	 traits	
other	than	their	MMR	status,	the	acquisition	of	
which	may	have	been	facilitated	by	inactivation	











cells	 treated	 with	 15	 mM	 cisplatin,	 which	 is	
equivalent	to	IC90	of	the	former	cells	(Fig.	1A),	
Figure 1. Cisplatin response in A2780 and CP70 
cells. (A) The response of A2780 and CP70 to 
increasing doses of cisplatin (CDDP) was determined 
in an MTT assay after 72 h. (B) Flow cytometric analy‑
ses of A2780 and CP70 cells treated with 15 mM 
cisplatin for the indicated times. (C and D) Western 
blot analyses of total cell extracts derived from the 
cells shown in panel B. IR (10 Gy), HU (2 mM) or UV 
(20 J/m2) were used as positive controls to assess the 
functionality of the checkpoint. TFIIH (panel C) and 
b‑tubulin (panel D) were used as loading controls. (E) 
Assessment of H2AX phosphorylation and nuclear 
foci formation in A2780 and CP70 cells treated with 
15 mM cisplatin for the indicated times. The antibody 
displayed a certain degree of diffused background 
staining in untreated cells, though foci appeared 
clearly in cisplatin‑treated cells.
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indicated	 that	 the	 treatment	 affected	 progression	 through	 the	 cell	
cycle	in	both	cell	lines	(Fig.	1B).	The	response	of	the	MMR-proficient	
A2780	 cells	 was	 characterized	 by	 a	 delayed	 transition	 through	
S-phase	 (Fig.	1B,	12–24	h)	prior	 to	G2	 arrest	 (Fig.	1B,	48	h)	 and	
triggering	 of	 apoptosis,	 as	 indicated	 by	 the	 presence	 of	 a	 sub-G1	
peak	 in	 the	 flow	 cytometric	 profile	 (Fig.	 1B,	 72	 h).	On	 the	 other	










CP70	cells	displayed	 a	 clear	 signal	 for	 the	phosphorylated	histone,	
thus	confirming	that	these	cells	reached	the	G2/M	transition	of	the	
cell	cycle	(Fig.	1C).
We	 then	 examined	 the	pattern	of	 cisplatin-induced	 signaling	 in	
A2780	and	CP70	cells.	A2780	displayed	rapid	 stabilization	of	p53	
and	transcriptional	induction	of	p21Waf1,	whereas	in	CP70	the	p53	
response	 was	 delayed	 and	 of	 smaller	 magnitude	 (Fig.	 1C).	 More	
importantly,	no	p21Waf1	was	detected	in	CP70	(Fig.	1C).	This	was	
likely	 due	 to	 lack	 of	 gene	 induction	 caused	 by	 the	 nonfunctional	
p53	 protein	 expressed	 in	 CP70	 cells,42	 rather	 than	 the	 result	 of	
protein	 degradation	 consequent	 to	 mitotic	 arrest,43	 since	 p21Waf1	
could	 not	 be	 detected	 at	 any	 time	 prior	 to	 the	 G2/M	 arrest	 or	
following	 reentry	 into	G1	 (Fig.	 1B	 and	C).	These	 data	 confirmed	
that	the	cisplatin-induced	p53	stabilization	in	CP70	cells	represents	
a	 nonproductive	 response.	 Checkpoint	 pathways	 were	 triggered	 in	
an	identical	manner	in	both	ovarian	cancer	cell	lines	(Fig.	1D).	This	
response	 consisted	 in	 activation	 of	 ATM	 and	 phosphorylation	 of	
its	 downstream	 targets	 CHK2,	 BRCA1	 and	 FANCD2.	The	 latter	
migrated	in	SDS-PAGE	as	a	doublet,	with	the	slower	migrating	band	
likely	 corresponding	 to	 mono-ubiquitylated	 FANCD2.44	 In	 this	














cells.	 The	 ability	 of	 CP70	 cells	 to	 resume	 progression	 through	
the	 cell	 cycle	 correlated	with	 a	 decrease	 in	 the	 size	 of	 gH2AX	 foci	
(Fig.	1E,	72	h),	which	may	be	 indicative	of	 either	 a	greater	 ability	
to	repair	DNA	damage	in	these	cells	or	of	reduced	induction	of	the	
DNA	repair	response	consequent	to	the	absence	of	MMR.
Figure 2. Cisplatin response in HCT116 and HCT116+chr3 cells. (A) Flow cytometric analysis of the semi‑isogenic, MMR‑proficient (HCT116+chr3) and 
MMR‑deficient (HCT116) cells treated with 15 mM cisplatin for the indicated times. (B and C) Western blot analyses of total cell extracts derived from the 




ways	 in	 the	 sensitive	and	resistant	cells	was	very	 similar	during	 the	
first	48	h,	indicating	that	the	presence	of	DNA	damage	was	equally	
well	 detected	 and	 signaled.	 However,	 the	 maintenance	 of	 intact	
homologous	 recombination	 machinery	 likely	 conferred	 a	 selective	
advantage	to	the	CP70	cells	in	bypassing	the	G2/M	arrest.
The Response to Cisplatin in Isogenic Systems.	 Loss	 of	DNA	
mismatch	 repair	 leads	 to	 genomic	 instability	 through	 an	 increased	
frequency	 of	 sporadic	 mutations	 in	 both	 coding	 and	 noncoding	
regions.	 To	 assess	 the	 role	 of	 MMR	 proteins	 in	 cisplatin-induced	
signaling	 more	 closely,	 we	 studied	 the	 drug	 response	 in	 matched	
pairs	of	MMR-deficient	and	-proficient	cell	lines.	In	HCT116+chr3,	
the	 lack	of	MLH1	in	the	colon	cancer	cell	 line	HCT116	has	been	
complemented	 by	 transfer	 of	 an	 additional	 copy	 of	 chromosome	
3,	 which	 carries	 the	 MLH1	 gene.34	 We	 found	 that	 treatment	 of	
asynchronous	 HCT116	 and	 HCT116+chr3	 cells	 with	 a	 concen-
tration	 of	 cisplatin	 equivalent	 to	 IC50	 for	 the	 proficient	 cell	
line,38	resulted	in	a	similar	response	in	the	two	cell	lines,	which	was	
Figure 3. Cisplatin‑treated HCT116+chr3 and HCT116 cells arrest at different points in the cell cycle. (A) HU‑synchronized HCT116±chr3 cells, untreated or 
treated with 15 mM cisplatin for the last 4 h of synchronization. After release, cell cycle progression was assessed by flow cytometry at the indicated times. 
(B) Western blot analyses of total cell extracts derived from the cells shown in panel A. (C) Indirect immunofuorescence of S‑phase and DNA damage mark‑
ers in HCT116+chr3 and HCT116 cells. Cells synchronized as in A were fixed and stained with antibodies against PCNA (red) or phosphorylated H2AX 




ment	 (Fig.	 2A).	 The	 overall	 pattern	 of	
protein	 phosphorylation	 observed	 in	
response	 to	 cisplatin	 also	 seemed	 to	 be	
similar	 in	 the	 two	 cell	 lines	 (Fig.	 2B	 and	
C).	 In	 both	 cases,	 the	 loss	 of	 viability	
that	 ensued	 upon	 prolonged	 arrest	 in	G2,	
was	 paralleled	 by	 degradation	 of	 DNA	
repair	 proteins	 (Fig.	 2B,	 72	 h).	However,	
closer	analysis	of	the	flow	cytometric	profile	
possibly	 revealed	 a	 slightly	 larger	 S-phase	
population	 in	 the	 HCT116+chr3	 cells	 at	
the	 24	 and	 48	 h	 time	 points	 (Fig.	 2A).	
In	 order	 to	 examine	 the	 cisplatin-induced	
S-phase	 delay	 observed	 in	 the	 mismatch	
proficient	HCT116+chr3	more	closely,	we	
analyzed	a	synchronized	population	of	cells.	






the	 HCT116	 cells	 accumulated	 at	 G2/M	
(Fig.	3A,	20–24	h	+	CDDP).	Accordingly,	
phosphorylation	 of	 histone	 H3	 was	 only	
detectable	 in	 HCT116	 (Fig.	 3B	 and	
Supplementary	 Fig.	 1).	 This	 confirmed	
that	 mismatch	 repair-proficient	 cells	 were	
blocked	 in	 late	 S-/early	 G2-phase.	 The	
presence	of	a	sub-G1	peak	in	HCT116+chr3	
cells	 from	 20	 h	 of	 treatment	 onward	




the	 sub-G1	 peak	 in	 the	 flow	 cytometric	 profiles	 (Fig.	 3A)	 and	 the	





replication,	 whereas	 the	 MMR-deficient	 HCT116	 cells	 displayed	
diffuse	PCNA	staining,	typical	of	cells	that	have	concluded	S-phase	
(Fig.	 3C).	 The	 S-phase	 delay	 was	 quantified	 by	 measuring	 the	
incorporation	 of	BrdU	 into	nascent	DNA:	 the	 data	 indicated	 that	
HU-released	 HCT116+chr3	 cells	 delayed	 their	 transition	 through	
S-phase	by	~4	h	in	response	to	cisplatin	(maximal	BrdU	incorpora-
tion	 at	 22	 h),	 as	 compared	 to	 the	MMR-deficient	HCT116	 cells	
(maximal	BrdU	incorporation	at	18	h)	(Supplementary	Fig.	2).	Foci	




h	 post-treatment.	HR	proteins	were	 not	 preferentially	 degraded	 in	
the	MMR-proficient	HCT116+chr3	cells,	but	disappeared	 in	both	
MMR-proficient	 and	 -deficient	 cells	 following	 the	 kinetics	 of	 cell	
death	(Fig.	2B).
Progression	of	cisplatin-treated	293T-La-/+	cells,	either	in	MMR-	
proficient	 or	 -deficient	 state,	 through	 the	 cell	 cycle	 (Fig.	 4A)	 and	
checkpoint	 activation	 in	 these	 cells	 (Fig.	 4B)	were	 similar	 to	 those	
observed	 in	 HCT116±chr3	 cells,	 except	 that	 the	 S-phase	 delay	
observed	 in	 the	 MMR-proficient	 HCT116+chr3	 cells	 was	 not	
evident	 in	 the	MMR-proficient	 293T-La+	 cells.	This	 is	 likely	 due	
to	the	fact	that,	among	other	possible	defects,	p53	in	the	latter	line	
has	been	inactivated	by	the	HPV	E6	and	the	SV40	large-T	antigens	




genic	 cell	 line	 HCT116+chr3,	 MMR	 proficiency	 correlates	 with	
the	 ability	of	 the	 cells	 to	 slow	down	 transition	 through	S-phase	 in	
response	to	cisplatin.	However,	whether	the	lack	of	S-phase	delay	in	
CP70	and	HCT116	depends	only	on	the	MMR	status	or	is	addition-
ally	 contributed	 to	 by	 the	 acquisition	 of	 other	 genetic	 alterations,	
cannot	be	established	at	 this	point.	Moreover,	 the	ability	 to	bypass	
the	G2/M	 checkpoint	 that	 accompanied	 cisplatin-resistance	 in	 the	
CP70	 cells	 examined	 in	 our	 study	 could	 not	 be	 attributed	 to	 the	
MMR-deficiency	 alone,	 since	 in	 the	 semi-isogenic	 HCT116	 cells	
and	 in	 the	 strictly	 isogenic	 setting	of	293T-La-/+	cells,	 such	bypass	
did	not	occur.





Figure 4. Cisplatin response of the strictly isogenic MMR‑deficient and –proficient 293T‑La‑/+ cells. 
(A) HU‑synchronized MMR‑proficient 293T‑La+ and MMR‑deficient 293T‑La‑ cells were treated with 
15 mM cisplatin and cell cycle progression was assessed by flow cytometry at the indicated times. 
(B) Western blot analyses of total cell extracts derived from the cells shown in (A).
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where	 it	 was	 shown	 that	 defective	 recombination	 conferred	 high	
sensitivity	to	cross-linking	agents	such	as	mitomycin	C	or	cisplatin.46	
Thus,	 downregulation	 of	 recombination	 by,	 for	 example,	 siRNA	
technology,	 would	 not	 only	 provide	 a	 strategy	 complementary	 to	
the	proposed	 inactivation	of	NER	as	a	means	 to	 interfere	with	 the	
repair	of	cisplatin-induced	damage,47	but	would	also	counteract	the	
emergence	 of	 cisplatin	 resistance	 through	 promoting	 the	 massive	
apoptotic	response	observed	in	A2780	cells.
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